ALDX Aldeyra TherapeuticsWatchlist
About Aldeyra Therapeutics Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Optimistic Outlook for Aldeyra Therapeutics Despite FDA Setback: A Strong Buy Rating
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) New Drug Application (NDA) of reproxalap, an investigational drug candidate for dry eye disease. Although no safe
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and ClearPoint Neuro (CLPT)
new drug application for reproxalap, a drug candidate for the treatment of dry eye disease, did not demonstrate efficacy.
The FDA also told Aldeyra that "at least one additional adequate and well-controlled study" should be conducted, the company said.
Aldeyra said it expects to resubmit the NDA in the first half of 2024, pending the FDA's feedback on the Special Pro...